prader willi glp 1 agonist Glucagon-like peptide-1 receptor: mechanisms and advances in therapy How GLP-1 Receptor Agonists Evolved
Description
[DOI] [PubMed] [Google Scholar] 135.Arterburn DE, Johnson E, Coleman KJ, et al
Recent evidence on these agonists highlighted their mechanisms in modulating neuroinflammation
Conflicts of Interest Maryam Lustberg is a consultant to Novartis, Lilly, Pfizer, Gilead, and Menarini
Factors favoring insulin therapy (Toujeo) Type 1 diabetes (absolute indication)
Clinical Trial Evidence The head-to-head comparison comes from the SURPASS clinical trial program for diabetes and SURMOUNT program for weight loss
JCL roundtable
